Brussels, Belgium — UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines, made a strategic investment in IMIDomics, a company focusing on developing medicines for immune-mediated inflammatory diseases.
The investment aims to support innovative solutions for patients with these conditions and potentially lead to collaborative research efforts between the two companies.
Update: Airbus Puts Up Zu As Board Member
Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCB said:
“This investment represents more than just financial support. It underscores our belief in IMIDomics’ potential and our commitment to fostering their pioneering efforts in the field of immune-mediated inflammatory diseases. We see this as an opportunity to contribute to enhancing patient care standards, and to collaboratively support the progression of medical innovation.”